| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.02 | 100.0% |
| Total Income | 0.02 | 100.0% |
| Expenditure | 8.06 | 47.9% |
| PBT | -1.06 | 105.7% |
| Net Profit | -0.06 | 100.3% |
| OPM | — | |
| NPM | — | |
| EPS | -4.42 | 445.3% |
PAVmed Reports Q1 2026 Financial Results and Business Update
15 May 2026 · 15 May, 5:41 pm
Summary
PAVmed Inc. reported financial results for the first quarter ended March 31, 2026. The company highlighted a simplified capital structure and strengthened balance sheet. Lucid Diagnostics recognized $1.3 million in EsoGuard revenue and processed 3,177 tests. The company's GAAP net loss attributable to common stockholders was approximately $7.0 million, or $(4.42) per common share. PAVmed had cash and cash equivalents of $6.5 million as of March 31, 2026.
Key Highlights
- 1
PAVmed now has a significantly simplified capital structure and strengthened balance sheet.
- 2
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission.
- 3
Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones.
- 4
Lucid Diagnostics recognized $1.3 million in EsoGuard® Esophageal DNA Test revenue for 1Q26 and processed 3,177 EsoGuard tests.
- 5
PAVmed ended 1Q26 with $6.5 million in cash and cash equivalents, compared to $1.5 million as of December 31, 2025.
- 6
GAAP net loss attributable to common stockholders was approximately $7.0 million, or $(4.42) per common share on a diluted basis for the three months ended March 31, 2026.
- 7
The Company’s non-GAAP adjusted loss was approximately $1.9 million or $(1.17) per common share for the three months ended March 31, 2026.
Management Comments
Lishan Aklog
M.D.
PAVmed now has a significantly simplified capital structure and strengthened balance sheet, positioning the Company to focus on execution across our core businesses and evaluate additional asset acquisition opportunities aligned with our long-term growth strategy. Veris continues to expand its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission, and Lucid continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage. We are also actively advancing multiple technologies within our relaunched medical device portfolio under Joseph Virgilio’s leadership, while increasingly leveraging his experience building and scaling growth-stage businesses.
Informational and educational content only. Not investment advice.